Drug intelligence / Profile preview

vitamin k2 + zinc citrate

Development stage: Preclinical
Lead developer: Abiogen
Modality: Small Molecules
Administration: Oral

Overview

Vitamin K2 + Zinc Citrate is an oral food supplement in IND-enabling development by Abiogen Pharma, an Italian pharmaceutical company. The product combines Vitamin K2 (menaquinone) and Zinc Citrate to target bone metabolism. Vitamin K2 acts as a cofactor for the gamma-carboxylation of vitamin-K-dependent proteins, such as osteocalcin and matrix Gla protein (MGP), which are critical for regulating calcium deposition in the bone matrix. Zinc Citrate provides a bioavailable form of zinc, an essential trace mineral that supports bone formation and mineral metabolism. This combination is intended to support bone health and is administered orally.

Other names: Vitamin K2 and Zn citrate

Targets

GGCX (Vitamin K-dependent gamma-glutamyl carboxylase)

Beyond the preview

Go deeper on vitamin k2 + zinc citrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vitamin k2 + zinc citrate.

Explore the full profile